Korro Bio, Inc. - 8-K Filing
Korro Bio terminates Novo Nordisk collaboration agreement and reports Q3 2026 net loss of $17.5 million (Items: 1.02 Termination of a Material Definitive Agreement, 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $KRRO